Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Atherosclerotic ischemic peripheral vascular disease or Thromboangiitis Obliterans with Critical Limb Ischemia (Fontaine stages III and IV)~* Participant must match either a or b~  1. Ankle brachial index (ABI) ≤ 0.7~ 2. Doppler waveforms at posterior tibial artery and dorsalis pedis artery are monophasic with toe pressure \< 30 mmHg.~* A non-surgical candidate for revascularization e.g. prior vascular reconstruction, inability to locate a suitable vein for grafting, diffuse multi- segment disease, or extensive infra-popliteal disease not amenable to a vascular graft.~* Age \> 18 years old.~* The non-index leg may be treated only in the event and it full fills the same eligibility criteria and exclusion criteria used in this protocol for the treatment leg.~* Patients must be on maximal tolerated medical therapy for PVD including A) Cessation of smoking B) Referral to endocrinologist for control of HgA1c to \< 7.0 mg/dl, control of hyperlipidemia with statins or other anti-hyperlipidemic drugs as indicated, control of hypertension as indicated C) Antiplatelet therapy with aspirin and / or cilostazol (unless medically contraindicated, e.g. bleeding or allergy)~Exclusion Criteria:~* Popliteal vascular entrapment syndrome~* Lower extremity infection or infected ulcer~* Hypercoagulable state~* HIV positive~* HBsAg positive~* Uncontrolled arrhythmia, that is, persistence of an arrhythmia despite medical therapy~* Unstable angina~* Thrombocytopenia \< 50,000/ul~* Leukemia or myelodysplasia~* Allergy to E coli or its products~* Patients with metal in their bodies cannot undergo MRIs (MRA). Therefore, patients with, cochlear implants, or aneurysm clips are not eligible. Coronary artery stents are not a contraindication. Patients with pacemakers are still candidates provided they have normal creatinine (\< 1.1 mg/dl) and can receive contrast dye (no allergy) for angiogram instead of MRA. MRI/MRA does not need to be repeated if a prior MRA or Angiogram Demonstrates inoperable disease.~* Patients who are pregnant~* Poorly controlled diabetes will not be a cause for exclusion but patient must see endocrinologist for better control~* Current malignancy, except squamous cell or basal cell skin cancers thought to be easily controlled.~* AST, ALT, or bilirubin more than twice the upper limit of normal.~* WBC \< 2.5 / ul.~* Any patient who is actively bleeding, including blood on urine dipstick or fecal occult blood.~* Patient is on chemotherapy or other immuno-suppressive medications such as steroids, cellcept, cyclosporine, cytoxan, azathioprine, rituxan, humira or remicade.~* Donor is HLA homozygous and shares that HLA haplotype with the recipient (a different donor will have to be found)~* Patients diagnosed with Thromboangiitis Obliterans (Buerger's Disease) who are smokers and are unwilling or unable to quit smoking~* A) Patients with a myocardial infarction within the last 30 days or left ventricular ejection fraction \< 35% B) Patients with a history of malignancy in the last 5 years (other than basal cell carcinoma or carcinoma in situ) C) Patients with a CVA within the last 6 months D) Patients with a HbA1c level \> 7.0%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- UBC injection into one leg of PVD pt (Type: EXPERIMENTAL): 25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues